Internal Reference Number: FOI_7822
Date Request Received: 12/03/2024 00:00:00
Date Request Replied To: 27/03/2024 00:00:00
This response was sent via: By Email
Request Summary: Urothelial and Endometrial Cancer
Request Category: Researcher
| Question Number 1: How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments: 鈥� Atezolizumab (Tecentriq) 鈥� Avelumab (Bavencio) 鈥� Carboplatin single agent or in any other combination 鈥� Carboplatin with Gemcitabine 鈥� Carboplatin with Paclitaxel 鈥� Cisplatin single agent or in any other combination 鈥� Cisplatin with Gemcitabine 鈥� Nivolumab (Opdivo) 鈥� Pembrolizumab (Keytruda) 鈥� Other active systemic anti-cancer therapy 鈥� Palliative care only | |
| Answer To Question 1: Please see attached responses for Q1, 3 and 4 To accompany this answer to question 1 please also see the documents listed below:  FOI_7822 - Urothelial and Endometrial Cancer response Q 1, 3 and 4.xlsx | |
| Question Number 2: Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments? | |
| Answer To Question 2: Yes, the Trust does provide SACT for such patients. Some patients will also receive this treatment at UHD (University Hospitals Dorset), if it is required alongside radiotherapy. | |
| Question Number 3: How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments: 鈥� Dostarlimab (Jemperli) 鈥� Hormone therapy (Progesterone or Letrozole) 鈥� Pembrolizumab (Keytruda) monotherapy 鈥� Pembrolizumab + Lenvatinib (Keytruda + Lenvima) 鈥� 鈥� Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) 鈥� Any other SACT | |
| Answer To Question 3: Please see attached responses for Q1, 3 and 4 | |
| Question Number 4: In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy? | |
| Answer To Question 4: Please see attached responses for Q1, 3 and 4 | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of 看片软件 Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
